文献速递免疫规划慢病防控与筛查

免疫调节治疗对免疫介导炎症性风湿病患者COVID-19疫苗免疫原性的影响:与健康对照比较的瑞典全国性研究(COVID19-REUMA)

The impact of immunomodulating treatment on the immunogenicity of COVID-19 vaccines in patients with immune-mediated inflammatory rheumatic diseases compared to healthy controls. A Swedish nationwide study (COVID19-REUMA).
PubMed 文献 · Vaccine · 2023-04-04

该瑞典全国性研究纳入接受生物/靶向改善病情抗风湿药(b/ts DMARDs)治疗的炎症性风湿病(IRD)患者414例及健康对照61例,比较第二剂和第三剂COVID-19疫苗后的抗体反应。作者建议利妥昔单抗患者应优先接种加强针。

要点

  • TNFi、JAKi和IL12/23/17i组第二剂后阳性抗体反应比例与对照组无显著差异。

核心结论

  • 高龄个体和接受维持性利妥昔单抗治疗的患者在接种两剂COVID-19疫苗后抗体反应受损,延长末次利妥昔单抗疗程与疫苗接种之间的时间以及增加一剂疫苗可改善反应。
  • 作者建议利妥昔单抗患者应优先接种加强疫苗剂量。
  • TNFi、JAKi和IL12/23/17i不削弱对基础接种和额外接种的体液反应。

研究设计与样本

  • 瑞典全国性研究,纳入五个瑞典地区接受b/ts DMARDs治疗的IRD患者414例(关节炎283例、系统性血管炎75例、其他自身免疫病56例)和对照61例。
  • 治疗组包括:利妥昔单抗(n=145)、阿巴西普(n=22)、IL-6受体抑制剂[IL6i(n=79)]、JAnus激酶抑制剂[JAKi(n=58)]、肿瘤坏死因子抑制剂[TNFi(n=68)]和IL-12/23/17抑制剂[IL12/23/17i(n=42)]。
  • 在接种前、第二剂后2-12周、第三剂前后,使用多重珠基血清学检测法测量针对全长刺突蛋白和刺突S1抗原的抗体水平。
  • 阳性抗体反应定义为:血清阴性个体抗体水平超过截断值(血清阳性),或对两种刺突蛋白均血清阳性的个体抗体水平≥4倍升高。

主要发现

  • 高龄、利妥昔单抗治疗以及末次利妥昔单抗疗程与疫苗接种之间时间较短预示抗体反应受损。

临床怎么用

  • 作者建议利妥昔单抗患者应优先接种加强疫苗剂量。
  • TNFi、JAKi和IL12/23/17i不削弱对基础接种和额外接种的体液反应。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To elucidate antibody responses after the second and third dose of COVID-19 vaccine in patients with inflammatory rheumatic diseases (IRD) treated with biologic/targeted disease modifying anti-rheumatic drugs (b/ts DMARDs). METHODS: Antibody levels to antigens representing spike full length protein and spike S1 were measured before vaccination, 2-12 weeks after the second dose, before and after the third dose using multiplex bead-based serology assay. Positive antibody response was defined as antibody levels over cut off (seropositivity) in seronegative individuals or ≥ 4-fold increase in antibodies in individuals seropositive for both spike proteins. RESULTS: Patients (n = 414) receiving b/ts DMARDs (283 had arthritis, 75 systemic vasculitis and 56 other autoimmune diseases) and controls (n = 61) from five Swedish regions participated. Treatments groups were: rituximab (n = 145); abatacept (n = 22); Interleukin 6 receptor inhibitors [IL6i (n = 79)]; JAnus Kinase Inhibitors [JAKi (n = 58)], Tumour Necrosis Factor inhibitor [TNFi (n = 68)] and Interleukin12/23/17 inhibitors [IL12/23/17i (n = 42)]. Percentage of patients with positive antibody response after two doses was significantly lower in rituximab (33,8%) and abatacept (40,9%) (p < 0,001) but not in IL12/23/17i, TNFi or JAKi groups compared to controls (80,3%). Higher age, rituximab treatment and shorter time between last rituximab course and vaccination predicted impaired antibody response. Antibody levels collected 21-40 weeks after second dose decreased significantly (IL6i: p = 0,02; other groups: p < 0,001) compared to levels at 2-12 week but most participants remained seropositive. Proportion of patients with positive antibody response increased after third dose but was still significantly lower in rituximab (p < 0,001). CONCLUSIONS: Older individuals and patients on maintenance rituximab have an impaired response after two doses of COVID-19 vaccine which improves if the time between last rituximab course and vaccination extends and also after an additional vaccine dose. Rituximab patients should be prioritized for booster vaccine doses. TNFi, JAKi and IL12/23/17i does not diminished humoral response to primary and an additional vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Frodlund M, Nived P, Chatzidionysiou A, et al. The impact of immunomodulating treatment on the immunogenicity of COVID-19 vaccines in patients with immune-mediated inflammatory rheumatic diseases compared to healthy controls. A Swedish nationwide study (COVID19-REUMA). Vaccine. 2023. PMID: 37076360. doi:10.1016/j.vaccine.2023.03.065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。